At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effects of AFQ056 on Language Learning in Young Children With Fragile X Syndrome (FXS)
In Brief
A Phase 2 clinical trial evaluating AFQ056, Placebo, and 1 other intervention for Fragile X Syndrome. Completed, enrolled 110 participants across 14 sites.
Detailed Summary
The purpose of this clinical trial is to investigate the impact of AFQ056 on language learning in 3-6 year old children with Fragile X Syndrome (FXS).
Study Details
Timeline
Interventions
12.5 mg - 100 mg oral suspension (liquid)
Placebo oral suspension (liquid)
All subjects will begin an intensive language intervention 2 months after starting treatment with AFQ056 or placebo and will continue the intervention through the end of the study. The language intervention will be administered by a trained language specialist through a combination of in clinic visits and at home synchronous video conferencing sessions. The intervention will subsequently be delivered to the parent by a speech-language clinician through weekly clinician coaching, homework, and feedback sessions. The language intervention is designed to help parents learn and use verbally responsive interactional strategies more frequently and effectively throughout the course of their daily interactions with their children.